Newer drugs for nonmetastatic CRPC underused

ANDROGEN deprivation therapy (ADT) combined with novel hormone therapies (NHTs) improves metastasisfree and overall survival among men with high-risk nonmetastatic castrationresistant prostate cancer (nmCRPC), but these regimens are underused in this patient population, according to study findings presented at the European Society for Medical Oncology’s 2022 Congress in Paris, France.

The findings are from a retrospective study of 2007-2020 data from the Optum electronic health records database. Sumati Gupta, MD, of Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues studied 1572 men with highrisk nmCRPC. As first-line treatment, 48.2% received ADT only, 32.9% received ADT plus first-generation nonsteroidal antiandrogens (NSAAs), 8.8% received ADT plus NHTs, and 10.1% received other regimens. As of 20182020, only 21% of patients received ADT plus NHTs (including those with a PSA doubling time of 4 months or less), whereas 44.5% received ADT alone and 26.2% received ADT plus NSAAs. Patients with PSA doubling time of 10 months or less are at high risk for metastatic disease. ■